Alexander Markov, MD
Endocrinology, Diabetes & Metabolism · Saint Peters, MONPI 1053806927
Payments from drug & device makers
Across 109 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$474
- Boehringer Ingelheim$200
- AstraZeneca$190
- Lilly USA, LLC$184
- Sequel Med Tech, LLC$159
- Amgen$148
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,37998%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $474 |
| Boehringer Ingelheim | 11 | $200 |
| AstraZeneca(2 entities) | 5 | $190 |
| Lilly USA, LLC | 11 | $184 |
| Sequel Med Tech, LLC | 2 | $159 |
| Amgen | 9 | $148 |
| Ascendis Pharma Endocrinology Inc | 1 | $108 |
| Mannkind Corporation | 4 | $108 |
| Xeris Pharmaceuticals, Inc. | 5 | $101 |
| Novartis | 5 | $87 |
| Sanofi-aventis U.S. LLC | 3 | $87 |
| Corcept Therapeutics | 4 | $85 |
| Pfizer | 4 | $70 |
| IBSA Pharma Inc. | 3 | $53 |
| Abbott | 2 | $42 |
| Antares Pharma, Inc. | 2 | $42 |
| Intuity Medical Inc | 2 | $37 |
| Dexcom, Inc. | 2 | $34 |
| Radius Health, Inc. | 1 | $25 |
| AbbVie | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Tris Pharma Inc | 1 | $18 |
| Tandem Diabetes Care, Inc. | 1 | $17 |
| Amphastar Pharmaceuticals, Inc. | 1 | $17 |
| Insulet Corporation | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| BETA Bionics, Inc. | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,439 in reported general payments places this provider in the 50th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 208 | $275,368 |
| JardianceEmpagliflozin | 78 | $99,365 |
| TrulicityDulaglutide | 51 | $82,011 |
| MounjaroTirzepatide | 67 | $81,892 |
| FarxigaDapagliflozin Propanediol | 80 | $75,719 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 32 | $31,602 |
| Tresiba Flextouch U-100Insulin Degludec | 51 | $28,640 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $26,733 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $11,444 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $10,154 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $9,614 |
| Novolog FlexpenInsulin Aspart | 35 | $9,216 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 18 | $8,636 |
| Gvoke Hypopen 2-PackGlucagon | 13 | $8,009 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $7,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $474 | $275,368208 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro | $184 | $164,605131 claims |
| Boehringer IngelheimJardiance | $200 | $99,36578 claims |
| AstraZenecaFarxiga | $190 | $75,71980 claims |
| AbbVieSynthroid | $25 | $3,30952 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Saint Peters
- Stanley MathewSaint Peters$37K
- Ranjani RamanathanSaint Peters$5K
- Ralph DudaSpringfield$3M
- Thomas NickolasSaint Louis$945K
- Anne GoldbergSaint Louis$830K
- Janet McGillSaint Louis$828K
- Christopher CaseJefferson City$692K
- Gregory LedgerSpringfield$690K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.